Discussion about this post

User's avatar
Karl Salnoske's avatar

I think the trick in this regulatory proposal is how to ensure it doesn’t become like the FDA. They have a tendency to move slowly on drug approvals, which means that many needed drugs are available first in other countries where the approval process moves faster. In healthcare, that can create medical tourism where US citizens are forced to go to other countries for treatments that aren’t available in the US. But in the case of AI, if we are slow to deploy the latest, most advanced AI models because they are held up in a US approval process, how do we compete with other countries where the models can be released faster?

No posts

Ready for more?